Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

What’s Driving the Pain? Alternative Approaches to Pain Management

Richard Quinn  |  February 26, 2018

Dr. Greer also recommends certain antidepressant medications, which “are used commonly for off-label chronic pain indications. Duloxetine, in particular, has indications approved by the FDA for chronic osteoarthritis pain and chronic fibromyalgia pain, along with the indication for depression and anxiety,” he notes.

Dr. Weselman says that, generally speaking acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) are a good start. For neuropathic pain, other types of medicine may be more appropriate, such as gabapentin, Lyrica and amitriptyline.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Inflammatory pain is going to respond better to anti-inflammatories and acetaminophen,” she adds. “Muscular pain is going to respond better to, perhaps, muscle relaxers. There’s a whole host of medications [that are not opioids] we can use to treat various types of pain. I think it’s important that we have that discussion with the patient, because I think patients think of pain medicine as being opioids, and if they don’t get an opioid, their pain isn’t being addressed.”

Dr. Weselman says the use of herbal supplements is a relatively unclear area, because not enough clinical evidence exists to support their efficacy. Dr. Greer says it’s a similar conundrum with medical marijuana, which may help alleviate pain in some patients, but needs additional study.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Challenges
Both rheumatologists agree there are times when the use of opioids is justified and necessary. But those situations are the doctor’s call—not the patient’s. One part of successfully using alternatives to opioids is ensuring patients feel their pain is being addressed.

In recent years, that’s been a trickier situation, because patients who use medical websites often feel they have a practical degree in pain management before a rheumatologist has spoken with them.

Dr. Google is always a problem, Dr. Greer notes. “Often, we have to do some myth debunking and spend a great deal of effort counseling the patient,” he says. “When it comes to chronic pain management, rheumatologists have an obligation to discuss with the patient that whatever treatment we give is designed to try to reduce their pain to a manageable level—but not eliminate pain entirely. I don’t think it’s realistic or appropriate to say we can get rid of all of your pain if it’s chronic.”

Dr. Greer, whose goal is to have patients report their pain level as 5 or lower on a 10-point scale, says it can be difficult when a patient he does not believe opioids are appropriate or has already been prescribed opioids by other rheumatologists—particularly patients diagnosed with fibromyalgia.

Page: 1 2 3 | Single Page
Share: 

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:Chronic painchronic pain patientsopioid alternativesOpioidsPainPain Management

Related Articles

    Speak Out Rheum: How Did We Go So Wrong with Opioid Prescribing?

    November 4, 2022

    I have been listening to The Fighter Pilot Podcast because my fantasy career would have been to fly a jet fighter plane (not even remotely possible, given my constitution). I learned that when an aircraft accident occurs, a mishap board is convened, not to assign blame but to try to learn what went wrong and…

    ah_designs / shutterstock.com

    The Perils of Pain Meds Revisited

    December 18, 2018

    More than 10 years ago, I wrote a commentary in The Rheumatologist, called “Perils of Pain Meds,” about the over-prescribing of opioid analgesics for common causes of chronic noncancer pain, which was a major contributor to the opioid epidemic.1 Since that time, although there has been a greater than 20% decrease in opioid prescribing, the…

    Rheumatologists Respond to Prescription Opioid Analgesic Crisis

    May 16, 2017

    The alarming statistics on prescription opioid overdoses are well known to medical professionals, thanks to the Centers for Disease Control and Prevention (CDC)’s widely cited finding that deaths from opioid analgesics have increased fourfold since 1999.1 Half of all fatal drug overdoses now involve opioids prescribed by a doctor. Meanwhile, a lack of rigorous research…

    10 Tips for Opioid Prescribing

    December 1, 2014

    How to manage the risks when prescribing medications for patients in chronic pain

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences